Get started
Author

Brett D. Williams

Observed name: Williams, Brett D.
ORCID: 0009-0004-8081-8925
Observed ORCID: 0009-0004-8081-8925
OpenAlex ID: A5112566680
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer
2022 · Meredith S. Eno, Jason D. Brubaker, et al. · Journal of Medicinal Chemistry · 202
PDF
An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva
2024 · Alison J. Davis, Natasja Brooijmans, et al. · Science Translational Medicine · 27
Supplementary Figure S2 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S5 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S6 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S6 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S8 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S7 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S4 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S8 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S5 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S2 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S1 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S1 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S7 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Data from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S3 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Table S3 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
Supplementary Figure S4 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al.
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
2026 · Alvin Ziying Lu, Brian B. Haines, et al. · Cancer Research
CCDC 965716: Experimental Crystal Structure Determination
2013 · Williams, Brett D., Smith, Amos B. · The Cambridge Structural Database
Works count: 21
Citation count: 229
H-index: 2
I10-index: 2
Year
Topic
Type